ANDA 87875, held by Vangard Labs. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 87875 (Procainamide Hydrochloride), held by Vangard Labs, was first approved by FDA on Jun 1, 1982, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 1982 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride500MG · capsule;oral | Procainamide Hydrochloride | Discontinued |
| Aug 11, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Jun 1, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters